IHE
Equity

iShares U.S. Pharmaceuticals ETF

NAV as ofMay 15, 2026
$87.8352 WK: 63.51 - 91.83
1 Day NAV Change as ofMay 15, 2026
Decrease $-1.65(-1.85%)
May 14, 2026
YTD: Increase 5.90%
Apr 30, 2026
1.25%
Apr 30, 2026
1.70%
Expense Ratio:Fees as stated in the prospectus
0.38%
4 stars
NAV as ofMay 15, 2026
$87.8352 WK: 63.51 - 91.83
1 Day NAV Change as ofMay 15, 2026
Decrease $-1.65(-1.85%)
May 14, 2026
YTD: Increase 5.90%
Apr 30, 2026
1.25%
Apr 30, 2026
1.70%
Expense Ratio:Fees as stated in the prospectus
0.38%
4 stars
The iShares U.S. Pharmaceuticals ETF seeks to track an index of U.S. companies in the pharmaceuticals sector. The fund offers a way for invstors to express a high-conviction view to domestic drug manufacturers and vaccine producers.

Key Facts

Net Assets of Fund
Fund Launch Date
Benchmark Index
Exchange
NYSE Arca
Shares Outstanding
9,900,000
as of May 15, 2026
0.01%
as of May 15, 2026
Closing Price
87.84
as of May 15, 2026
0.09%
as of May 15, 2026
Asset Class
Equity
Bloomberg Index Ticker
DJSPHMT
Quarterly
CUSIP
464288836
106,175.00
as of May 15, 2026
71,796.00
as of May 15, 2026

Portfolio Characteristics

15.84%
as of Apr 30, 2026
4.50
as of May 14, 2026
0.53
as of Apr 30, 2026
23.21
as of May 14, 2026

This information must be preceded or accompanied by a current prospectus. For standardized performance, please see the Performance section.

More Funds to Consider

BMED
iShares Health Innovation Active ETFView BMED
THRO
iShares U.S. Thematic Rotation Active ETFView THRO

Holdings

Holdings are subject to change.


The values shown for “market value,” “weight,” and “notional value” (the “calculated values”) are based off of a price provided by a third-party pricing vendor for the portfolio holding and do not reflect the impact of systematic fair valuation (“the vendor price”). The vendor price is not necessarily the price at which the Fund values the portfolio holding for the purposes of determining its net asset value (the “valuation price”). Holdings data shown reflects the investment book of record, which may differ from the accounting book of record used for the purposes of determining the Net Assets of the Fund. Notional value represents the portfolio's exposures based on the economic value of investments and options are delta-adjusted. Additionally, where applicable, foreign currency exchange rates with respect to the portfolio holdings denominated in non-U.S. currencies for the valuation price will be generally determined as of the close of business on the New York Stock Exchange, whereas for the vendor price will be generally determined as of 4 p.m. London. The calculated values may have been different if the valuation price were to have been used to calculate such values. The vendor price is as of the most recent date for which a price is available and may not necessarily be as of the date shown above.

Please see the “Determination of Net Asset Value” section of each Fund’s prospectus for additional information on the Fund’s valuation policies and procedures.

“Quantity” represents the number of shares, units or contracts of the corresponding security, as applicable per security type.

Exposure Breakdowns

Sector
% of Market Value as of May 14, 2026
Pharmaceuticals99.86%
Cash and/or Derivatives0.14%

Allocations are subject to change.

Ratings

Rated by Morningstar
4 stars
Overall Morningstar Rating for iShares U.S. Pharmaceuticals ETF, as of Apr 30, 2026 rated against 164 Health Funds based on risk adjusted total return.

Performance

1y3y5y10yIncept.
Total Return (%)
25.1715.949.848.2410.27
Market Price (%)
25.2316.009.828.2610.27
Benchmark (%)
25.4116.2410.118.5310.65
After Tax Pre-Liq. (%)
24.6015.489.387.859.92
After Tax Post-Liq. (%)
15.2212.467.706.628.86

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted.

-

The Hypothetical Growth of $10,000 chart reflects a hypothetical $10,000 investment and assumes reinvestment of dividends and capital gains. Fund expenses, including management fees and other expenses were deducted.

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted, and numbers may reflect small variances due to rounding. Standardized performance and performance data current to the most recent month end may be found in the Performance section.

Distributions

Mar 17, 2026Mar 17, 2026Mar 20, 2026$0.284491$0.284491$0.000000$0.000000$0.000000
Dec 16, 2025Dec 16, 2025Dec 19, 2025$0.585254$0.585254$0.000000$0.000000$0.000000
Sep 16, 2025Sep 16, 2025Sep 19, 2025$0.312397$0.312397$0.000000$0.000000$0.000000
Jun 16, 2025Jun 16, 2025Jun 20, 2025$0.306536$0.306536$0.000000$0.000000$0.000000
Mar 18, 2025Mar 18, 2025Mar 21, 2025$0.291667$0.291667$0.000000$0.000000$0.000000
Dec 17, 2024Dec 17, 2024Dec 20, 2024$0.210819$0.210819$0.000000$0.000000$0.000000
Sep 25, 2024Sep 25, 2024Sep 30, 2024$0.358883$0.358883$0.000000$0.000000$0.000000
Jun 11, 2024Jun 11, 2024Jun 17, 2024$0.294016$0.294016$0.000000$0.000000$0.000000
Mar 22, 2024Mar 21, 2024Mar 27, 2024$0.275023$0.275023$0.000000$0.000000$0.000000
Dec 21, 2023Dec 20, 2023Dec 27, 2023$0.134737$0.134737$0.000000$0.000000$0.000000
Showing 1 to 10 of 81

Fees

as of current prospectus
Management Fee
0.38%
0.00%
Other Expenses
+0.00%

0.38%

The amounts shown above are as of the current prospectus, but may not include extraordinary expenses incurred by the Fund over the past fiscal year. Amounts are rounded to the nearest basis point, which in some cases may be "0.00".

This fund does not seek to follow a sustainable, impact or ESG investment strategy. For more information regarding the fund's investment strategy, please see the fund's prospectus or, as applicable, shareholder report.